tezspire
astrazeneca ab - tezepelumab - astma - zāles obstruktīvu elpceļu slimību, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
beyfortus
astrazeneca ab - nirsevimab - un imūnglobulīni, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiski līdzekļi - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
crestor 20 mg apvalkotās tabletes
grünenthal gmbh, germany - rosuvastatīns - apvalkotā tablete - 20 mg
crestor 10 mg apvalkotās tabletes
grünenthal gmbh, germany - rosuvastatīns - apvalkotā tablete - 10 mg
atacand plus 16 mg/12,5 mg tabletes
cheplapharm arzneimittel gmbh, germany - candesartanum cilexetilum, hydrochlorothiazidum - tablete - 16 mg/12,5 mg
atacand 8 mg tabletes
cheplapharm arzneimittel gmbh, germany - kandesartāna cileksetils - tablete - 8 mg
atacand 16 mg tabletes
cheplapharm arzneimittel gmbh, germany - kandesartāna cileksetils - tablete - 16 mg
betaloc zok 50 mg ilgstošās darbības tabletes
recordati industria chimica e farmaceutica s.p.a., italy - metoprolola sukcināts - ilgstošās darbības tablete - 50 mg
betaloc zok 100 mg ilgstošās darbības tabletes
recordati industria chimica e farmaceutica s.p.a., italy - metoprolola sukcināts - ilgstošās darbības tablete - 100 mg